Can Gabapentin Cause Brain Fog?

Gabapentin can cause brain fog, and among people who report negative experiences with the drug, cognitive cloudiness is the single most common complaint. The term “brain fog” is informal, but it captures a real cluster of symptoms: difficulty concentrating, sluggish thinking, trouble finding words, and a general sense that your mental sharpness has dulled. These effects stem from the way gabapentin quiets nerve signaling in the brain, and they tend to be worst during the first days or weeks of treatment. What makes the picture more complicated is that the severity varies enormously depending on dose, kidney function, age, and what other medications you take.

How Gabapentin Affects the Brain

Gabapentin was originally developed as an anti-seizure medication and is now prescribed widely for nerve pain, restless legs syndrome, and certain anxiety disorders. Despite its name suggesting a connection to the neurotransmitter GABA, the drug does not actually work through GABA receptors. Instead, it binds to a specific part of voltage-gated calcium channels in the nervous system, reducing the flow of calcium into nerve terminals.¹ That reduced calcium flow means neurons release fewer signaling chemicals at their synapses.²

This is exactly why gabapentin helps with pain and seizures: it tones down overactive nerve signaling. But the effect is not perfectly targeted. The same calcium channel subunit that gabapentin binds to is found throughout the brain, including in areas responsible for memory, attention, and processing speed. When neurotransmitter release drops in those regions, the result can be the mental sluggishness people describe as brain fog.

There is another layer to this. Research published in Cell found that the calcium channel subunit gabapentin targets also plays a role in the formation of new excitatory connections between neurons. By blocking this process, gabapentin can inhibit the creation of new synapses.³ This mechanism was initially studied in the context of pain circuits, where preventing unwanted new connections between sensory and spinal cord neurons is therapeutic.⁴ Whether this synapse-blocking effect meaningfully contributes to cognitive side effects in humans is still an open question, but it adds a plausible biological pathway beyond simple neurotransmitter suppression.

What Patients Actually Report

Clinical trial data lists dizziness, drowsiness, and fatigue as gabapentin’s most frequent side effects, and those overlap heavily with what people experience as brain fog. But the way patients describe their cognitive problems in their own words goes further than trial adverse-event categories capture. An analysis of public social media posts about gabapentin and related drugs found that brain fog was the most commonly reported adverse symptom among users sharing negative experiences, outranking even pain relief failure and withdrawal complaints.⁵

In a small clinical study of people with spinal cord injuries who began gabapentin, formal neuropsychological testing showed measurable cognitive decline across several domains within the first week of starting the drug. Scores on six out of nine cognitive tests dropped compared to baseline. The encouraging detail was that most of those scores improved again by the four-week mark, suggesting the brain adapts to the drug over time for many people.⁶ This pattern, where cognitive side effects are sharpest during the early titration period and then ease, matches what clinicians frequently observe in practice.

Dose and How Quickly You Ramp Up

The speed at which gabapentin is introduced plays a real role in how much brain fog you experience. A standard titration schedule starts at 300 mg on the first day and increases by 300 mg daily over three days, reaching 900 mg by day three, with further increases up to 1,200 mg or more in the following days. Adverse effects like drowsiness, dizziness, and a general feeling of being mentally “off” are frequently reported during this titration phase, and they are the most common reasons people stop the drug altogether.⁷

There is evidence that spreading the same total daily dose into more frequent smaller doses helps. In one study, splitting the daily gabapentin dose into four administrations rather than three produced significantly fewer side effects, including less dizziness and drowsiness, over a two-week period.⁷ The reasoning is straightforward: smaller individual doses mean lower peak drug levels in the blood, and it is those peaks that tend to produce the most cognitive dulling. If you are struggling with brain fog on gabapentin, asking your prescriber about a slower titration or more divided dosing is a reasonable conversation to have before concluding the drug does not work for you.

Kidney Function Is a Major Risk Factor

Gabapentin is eliminated almost entirely by the kidneys, unchanged. If your kidneys are not clearing the drug efficiently, blood levels climb higher than intended, and so do side effects. This is not a minor footnote. A retrospective study found that the risk of hospitalization for altered mental status at higher gabapentin doses was significantly greater in patients with chronic kidney disease than in those without it.⁸

More strikingly, a recent preprint analysis comparing gabapentin to pregabalin found that among patients without kidney disease, the two drugs carried roughly similar cognitive risk. But among patients with chronic kidney disease who were not on dialysis, gabapentin was associated with a dramatically higher risk of dementia compared to pregabalin.⁹ The study authors described the kidney-disease-stratified difference as the dominant finding. This makes pharmacological sense: if the drug accumulates because your kidneys cannot clear it, you are effectively getting a higher dose than prescribed, and the cognitive effects scale accordingly. People with even mildly reduced kidney function should have their gabapentin doses adjusted downward, something that does not always happen in practice.

Older Adults Face Compounding Risks

Age adds another layer of vulnerability. Kidney function declines naturally with age, which means older adults often have higher-than-expected gabapentin levels even at standard doses. On top of that, the aging brain is more sensitive to the sedating and cognitive effects of centrally acting drugs. Older adults are also more likely to be taking multiple medications, each of which can contribute its own cognitive burden.

In the population-based study of gabapentin doses and altered mental status, the study cohort consisted of older adults, and the risk was clearly dose-dependent.⁸ For elderly patients, confusion or sudden cognitive decline after starting gabapentin should prompt immediate medical attention rather than a wait-and-see approach.

When Other Medications Are Involved

Gabapentin’s cognitive effects intensify when combined with other sedating drugs. This is especially relevant for people taking opioid pain medications, a common pairing in chronic pain management. A study of people with HIV who were on chronic opioid therapy found that adding gabapentin was significantly associated with trouble thinking clearly, even after adjusting for opioid dose, other sedating medications, and mental and physical health factors. About 40 percent of the participants who were prescribed gabapentin alongside opioids reported difficulty thinking clearly.¹⁰

Benzodiazepines, sleep aids, antihistamines, and muscle relaxants all share sedating properties with gabapentin. Combining any of these can push cumulative cognitive side effects past a person’s tolerance threshold even when each drug individually might be manageable. If you are on gabapentin and also taking any of these other medication categories, that combination is worth flagging to your doctor as a potential contributor to brain fog.

Long-Term Use and Dementia Risk

The question that worries many people most is whether gabapentin’s cognitive effects might not be just temporary but could signal or contribute to lasting cognitive decline. Several large observational studies have now examined this, and the results deserve careful reading.

A Taiwanese study using national health insurance data found that people exposed to gabapentin or pregabalin had a roughly 45 percent higher risk of developing dementia compared to matched unexposed controls. The risk went up with higher cumulative doses, and it was actually most pronounced in younger patients under 50, who had over three times the risk of the older groups.¹¹ A separate study of chronic low back pain patients found that those with six or more gabapentin prescriptions had about a 29 percent higher incidence of dementia. Among non-elderly adults prescribed gabapentin, the risk was roughly double for both dementia and mild cognitive impairment compared to those not prescribed the drug.¹²

These numbers are attention-getting, but the studies have important limitations that prevent drawing a direct causal line. They are observational, meaning they can identify associations but not prove that gabapentin itself causes dementia. People who are prescribed gabapentin often have chronic pain, sleep disruption, depression, or other conditions that independently raise dementia risk. Chronic pain itself is associated with cognitive decline, and the underlying conditions being treated, not just the treatment, could be driving some of the observed signal. The kidney disease findings discussed earlier suggest that at least part of the risk may be pharmacokinetic: drug accumulation rather than an inherent neurotoxic property. Still, these studies are large enough and consistent enough that long-term cognitive effects deserve ongoing monitoring, especially for people on high doses or with impaired kidney function.

Gabapentin and Pregabalin Compared

Gabapentin and pregabalin are often discussed together because they share the same mechanism of action. A systematic review and meta-analysis looking at the memory effects of both drugs in clinical and preclinical studies found that short-term pregabalin use in healthy volunteers produced transient central nervous system side effects, though the clinical studies were too few and too varied to combine into a formal statistical analysis.¹³ In a head-to-head comparison of several non-opioid pain medications on daytime cognitive performance, pregabalin increased tracking errors on laboratory tasks measuring psychomotor speed, suggesting it too impairs daytime functioning.¹⁴ Pregabalin is absorbed more predictably and reaches peak blood levels faster, which means its cognitive effects can feel sharper but also more predictable in timing. Gabapentin’s absorption becomes less efficient at higher doses, making its blood levels less predictable and its side effects less consistent from dose to dose.

The kidney disease data noted earlier suggests that, in people with normal kidney function, the cognitive risk profiles of gabapentin and pregabalin are not dramatically different. The gap opens wide for patients with kidney problems, where gabapentin’s exclusive reliance on renal clearance becomes a liability that pregabalin, which also depends on kidney clearance but has more predictable pharmacokinetics, seems to handle somewhat better.

Effects on Driving and Real-World Function

Brain fog is not just an abstract complaint about feeling mentally cloudy. It translates into measurable impairment in real-world tasks. A forensic review of drugged driving investigations found cases where gabapentin was the only drug present and the driver exhibited lane departures and at-fault crashes consistent with the drug’s known adverse effects.¹⁵ A randomized study in healthy volunteers directly measured simulated driving performance, sedation, and cognitive function after administration of gabapentin and related drugs.¹⁶

These findings matter because many people taking gabapentin are otherwise healthy enough to drive, work, and carry on normal activities. The cognitive dulling can be subtle enough that you do not feel dramatically impaired, yet measurable enough to slow your reaction time or compromise your ability to track a moving object. During the first week or two on the drug, or after a dose increase, being cautious about driving and other safety-critical tasks is sensible.

The Sleep Angle

Here is where gabapentin’s relationship with cognition gets more nuanced. A review of objective sleep data found that gabapentin reduces the time it takes to fall asleep and improves sleep efficiency.¹⁷ For people whose pain or nerve symptoms are disrupting their sleep, better sleep quality can actually improve daytime cognitive function overall. This creates a paradox: the same drug that directly dulls cognition through neurotransmitter suppression may indirectly sharpen it by restoring restorative sleep.

In practice, this means some people experience net cognitive improvement on gabapentin, particularly if their pre-treatment brain fog was driven more by terrible sleep than by anything else. Others experience net cognitive worsening because the direct sedating effect outweighs the sleep benefit. Whether you fall into one camp or the other depends heavily on your starting point and your dose. People who were sleeping relatively well before starting gabapentin are more likely to notice pure cognitive blunting; those who were severely sleep-deprived may notice their thinking actually clearing up after a few weeks, once the initial adjustment period passes.

A Surprising Finding in Animal Research

One wrinkle that complicates the narrative further comes from preclinical research. A study in mice found that gabapentin at lower doses actually improved spatial and emotional cognitive performance across multiple standard memory tests. Treated mice spent more time in the correct area of a water maze, learned avoidance tasks faster, and showed better retention of learned information compared to untreated controls.¹⁸

Animal data does not directly predict human experience, and the doses used in mouse studies do not map neatly onto human therapeutic doses. But this finding suggests that the relationship between gabapentin and cognition is not a simple one-way street of impairment. At certain doses and under certain conditions, the drug’s effects on neural circuitry might tip the balance toward enhanced rather than diminished cognitive function. Whether this has any practical relevance for human patients remains speculative, but it is a useful reminder that “gabapentin causes brain fog” is an oversimplification of a more complex pharmacological reality. The drug modulates brain activity broadly, and the net cognitive outcome for any given person depends on what was happening in their brain before they started taking it.